Laboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.
Created in 2008, Laboratoire Dazont is a France-based company specialized in the design, manufacture and distribution of natural veterinary solutions for pharmacies and parapharmacies. The company offers a complete range of approximately 50 references of natural products, including aromatherapy, petcare, and products and food supplements for dogs and cats under the Vetoform and Vetonut brands. Laboratoire Dazont offers its solutions to 750 pharmacies and parapharmacies in France, including key accounts such as E. Leclerc and Santédiscount.
Created in 1994, SBM Company is a family-owned French group with presence in more than 31 countries throughout Europe and North America. SBM designs, homologates, produces and markets products for the care and protection of crops, gardens and homes. In 2021, the group generated approximately US$360 million in sales, 60% internationally.
Oaklins’ team in France acted as M&A advisor to Laboratoire Dazont in the disposal of the company to SBM Company.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more